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ABSTRACT 
BACKGROUND AND OBJECTIVE 
Diabetes is one of the most common co-morbid illness in our 
community. Objective of this study is that the following two ulcer 
classification systems were applied to new foot ulcers to compare them as 
predictors of outcome: the Wagner (grade) and the University of Texas 
(UT) (grade and stage) wound classification systems 
To describe the lesions we treat study and compare outcomes and to 
identify measures to decrease morbidity and mortality due to diabetic foot 
disease 
METHODS 
 Between July 2016 and September 2016, 50 patients with diabetic 
foot who got admitted to Institute of General Surgery,Rajiv Gandhi 
Government General Hospital,Chennaiwere subjected to surgical 
treatment depending upon the Wagner’s classification and university of 
texas classification sytem. Data was collected and analyzed. 
 
 
 
RESULTS 
 Majority of the patients came with poor glycemic control at the 
time of presentation. Conservative management with antibiotics was 
useful in some patients. Most number of patients needed surgical 
treatment either in the form of debridement or amputation. 
INTERPRETATION AND CONCLUSION 
Patient education and strict glycemic control can reduce the burden 
of diabetic foot. Early diagnosis and hospitalization, appropriate 
treatment including medical and surgical treatment according to the grade 
can reduce the morbidity mortality and improve the outcome of the 
disease. Increasing stage, regardless of grade, is associated with 
increaseed risk of amputation and prolonged ulcer healing time. The UT 
system’s inclusion of stage makes it a better predictor of outcom 
 
KEY WORDS: Antibiotics; Amputation; Wagner classification; 
Complications; Glycemic control. 
  
  
  
“Wagner’s Classification for diabetic foot disease (adopted from 
Levin and O’Neals)” 
Grade Description 
Grade 0 High risk foot and no ulceration 
Grade 1 Superficial Ulcer; Total destruction 
of the thickness of the skin  
Grade 2 Deep Ulcer (cellulitis); Penetrates 
through skin,fat,ligaments not 
affecting bone 
Grade 3 Osteomyelitis with Ulceration or 
abscess 
Grade 4 Gangrenous patches limited to toes 
or part of the foot 
Grade 5 Gangrene of the entire foot  
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          Introduction 
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INTRODUCTION 
Four categories of diabetes are recognized. Type 1, formerly 
insulin-dependent diabetes mellitus (IDDM), is an autoimmune disease 
affecting the pancreas. Individuals with type 1 diabetes are prone to 
ketosis and unable to pro- duce endogenous insulin. Type 2, formerly 
non-insulin dependent diabetes mellitus (NIDDM), accounts for 90% to 
95% of cases diagnosed. Type 2 diabetes is characterized by 
hyperglycemia in the presence of hyperinsulinemia due to peripheral 
insulin resistance. Gestational as well as genetic defects and 
endocrinopathies are recognized as other types of diabetes (11). Diabetes 
is associated with numerous complications related to microvascular, 
macrovascular, and metabolic etiologies. These include cerebrovascular, 
cardio- vascular, and peripheral arterial disease; retinopathy; neu- 
ropathy; and nephropathy. Currently, cardiovascular com- plications are 
the most common cause of premature death. Diabetes continues to de  
one  of  the most common underlying cause of non-traumatic lower 
extremity amputations (LEAs) 
Epidemiology (INT. J. DIAB. DEV. COUNTRIES (1994), VOL. 14) 
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  “Mean age at diagnosis of diabetic foot and mean age at 
major amputation was significantly lower as compared to Western 
literature. This should be the sole reason to explain favourable results 
seen in our series specially in reference to survival at 2 years after 
major amputation, contralateral limb amputation rate, above knee to 
below knee amputation rate. Older patients reported in Western literature 
are more likely to have advanced atherosclerotic disease involving heart, 
cerebral circulation, peripheral circulation and renal circulation thus 
adversely affecting mortality and contralateral limb amputation rate. 
Above knee amputation was common in Western population and above 
knee to below knee amputation ratio was 1:2 vs. 1:17 in Western vs. our 
series.” 
“Majority of our patients have infection as  a dominant feature in 
non-neuroischemic foot. In such cases local debridement, control of 
infection and diabetes, certainly improves the limb salvage. If the 
infection is fulminant, minor or at the most below knee amputation is 
enough to stop the advancing infective process. As against this in 
Western patients, where old age and neuroischemic limbs are common, 
advanced atherosclerosis, and multi- system involvement makes above 
knee amputation perhaps the right choice to reduce the overall 
mortality.” 
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“In one population-based study in Sweden (1) the cost of treating 
foot ulcer was US$ 14,627 as compared to US$ 500 in our  patients. The  
cost    of treatment in-patients undergoing amputation was US$ 73,702 in 
Sweden as compared to US$ 2000 in our patients. This difference in cost 
of treatment is obviously due to marked economic disparity in two 
populations. Although cost of private treatment in India is less, majority 
of our patients have to  bear the entire cost of the treatment as they are 
not medically insured and for them even this cost is substantial.” 
“Although present study shows favourable results in Indian 
patients as compared to Western, it will not be surprising if one sees the 
change in scenario in next ten to thirty years. In India the number of 
amputation in diabetic patients is bound to increase due to several factors 
like increasing prevalence of diabetes, longer survival, more ageing 
population, continued use of tobacco, barefoot walking, careless home 
surgical attempt, late reporting to medical centre and poor hygienic 
conditions. Unless urgent steps are taken, India might emerge as  a 
country with highest rate of amputations for diabetic foot.” 
 
 
5  
AIMS AND OBJECTIVES 
       The purpose of this dissertation is to compare wagners and 
university of texas scoring system in diabetic foot management at 
Institute of General surgery, Rajiv Gandhi Government General Hospital, 
Chennai. 
    The study period is between March 2016 to September  2016. 
1. To evaluate and manage the different lesions of diabetic foot 
according to Wagner classification and university of texas scoring 
system. 
2. To describe the lesions we treat study and compare outcomes. 
3. To identify measures to decrease morbidity and mortality due to 
diabetic foot disease. 
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Review Of 
Literature
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REVIEW OF LITERATURE 
`“Diabetic foot ulcers occur as a result of various factors, such 
as mechanical changes in conformation of the bony architecture of the 
foot, peripheral neuropathy, and atherosclerotic peripheral arterial 
disease, all of which occur with higher frequency and intensity in the 
diabetic population.” 
Risk for Ulceration 
“Foot ulceration is the most common single precursor to lower 
extremity amputations among persons with diabetes (28-30). Treatment 
of infected foot wounds comprises up to one quarter of all diabetic 
hospital admissions , making this the most common reason for diabetes- 
related hospitalization in these countries (41-43). The multifactorial 
nature of diabetic foot ulceration has been elucidated by numerous 
observational studies (16, 22, 24, 26, 27, 44-48). Risk factors identified 
include peripheral neuropathy, vascular disease, limited joint mobility, 
foot deformi- ties, abnormal foot pressures, minor trauma, a history of 
ulceration or amputation, and impaired visual acuity (25, 49, 50). These 
and other putative causative factors are shown in Figure 1.” 
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Figure 1 The risk factors for ulceration may be distinguished by 
general or systemic considerations versus those localized to the foot and 
its pathology. 
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“Peripheral sensory neuropathy in the face of unperceived trauma 
is the primary factor leading to diabetic foot ulcerations (24, 27, 46, 49). 
Approximately 45% to 60% of all diabetic ulcerations are purely 
neuropathic, while up to 45% have neuropathic and ischemic components 
(24, 51). According to an important prospective multicenter study, 
sensory neuropathy was the most frequent component in the causal 
sequence to ulceration in diabetic patients (24).” 
“Other forms of neuropathy may also play a role in foot 
ulceration. Motor neuropathy resulting in anterior crural muscle atrophy 
or intrinsic muscle wasting can lead to foot deformities such as foot drop, 
equinus, hammertoe, and prominent plantar metatarsal heads (25, 26, 52-
54). Ankle equinus with restricted dorsiflexory range of motion is fairly 
common in patients with diabetic neuropathy and can be a consequence 
of anterior crural muscle atrophy (55-60). The decreased ankle motion, 
which confers higher-than- normal plantar pressures at the forefoot, has 
been implicated as a contributory cause of ulceration as well as 
recurrence or recalcitrance of existing ulcers (57, 58, 60, 61).” 
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“Autonomic neuropathy often results in dry skin with cracking and 
fissuring, creating a portal of entry for  bacteria (42, 63). Auto-
sympathectomy with attendant sympathetic failure, arteriovenous 
shunting, and microvascular thermoregulatory dysfunction impairs 
normal tissue perfusion and microvascular responses to injury. These 
alterations can subsequently be implicated in the pathogenesis of 
ulceration (63-67).” 
“Foot deformities resulting from neuropathy, abnormal 
biomechanics, congenital disorders, or prior surgical inter- vention may 
result in high focal foot pressures and increased risk of ulceration (24, 
48, 50, 57, 68-71). The effects of motor neuropathy occur relatively 
early and lead to foot muscle atrophy with consequent development of 
hammertoes, fat pad displacement, and associated increases in plantar 
forefoot pressures (53, 72-75). Although most deformities cause high 
plantar pressures and plantar foot ulcerations, medial and dorsal 
ulcerations may develop as a result of footwear irritation. Common 
deformities might include prior partial foot amputations, prominent 
metatarsal heads, hammertoes, Charcot arthropathy, or hallux  
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valgus (69, 76-79). A large prospective population-based study 
found that elevated plantar foot pressures are significantly associated 
with neuropathic ulceration and amputation (80). The study also revealed 
a trend for increased foot pressures as the number of pedal deformities 
increased.” 
Trauma to the foot in the presence of sensory neuropathy is an 
important component cause of ulceration (24). While trauma may 
include puncture wounds and blunt injury, a common injury leading to 
ulceration is moderate repetitive stress associated with walking or day-to-
day activity (69, 76, 81).  This is often manifested by callus formation 
under the metatarsal heads (48, 82, 83). A recent report suggests that 
even with moderate activity, ulceration may be precipitated by a higher 
degree of variability in activity or period- ic “bursts” of activity (84). 
Shoe-related trauma has also been identified as a frequent precursor to 
foot ulceration (28, 51, 54, 85, 86). 
“Peripheral arterial disease (PAD) rarely leads to foot ulcerations 
directly. However, once ulceration develops, arterial insufficiency will 
result in prolonged healing, imparting an elevated risk of amputation (28, 
87, 88). Additionally, attempts to resolve any infection will be impaired 
due to lack of oxygenation and difficulty in delivering antibiotics to the 
12 
 
infection site. Therefore, early recognition and aggressive treatment of 
lower extremity ischemia are vital to lower limb salvage (30, 52, 89-91).” 
“Limited joint mobility has also been described as a potential risk 
factor for ulceration (92-94). Glycosylation of collagen as a result of 
longstanding diabetes may lead to stiffening of capsular structures and 
ligaments (cheiroarthropa- thy) (95).  
The subsequent reduction in ankle, subtalar, and first 
metatarsophalangeal (MTP) joint mobility has been shown to result in 
high focal plantar pressures with increased ulceration risk in patients with 
neuropathy (92, 96, 97). Several reports also attribute glycosylation and 
altered arrangement of Achilles tendon collagen to the propensity for 
diabetic patients to develop ankle equinus (98, 99).” 
Other factors frequently associated with heightened ulceration risk 
include nephropathy, poor diabetes control, duration of diabetes, visual 
loss, and advanced age (48,  69, 
13 
 
 
Figure 2     Diabetes mellitus is responsible for a variety of foot 
pathologies contributing to the complications of ulceration and 
amputation. Multiple pathologies may be implicated, from vascular 
disease to neuropathy to mechanical trauma. 
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93, 100). Soft tissue changes (other than cheiro arthropathy) in the 
feet of diabetic patients might also contribute to ulceration through the 
pathway of altered pressure distributions through the sole of the foot. 
Such alterations include a reported increased thickness of the plantar 
fascia with associated limitation of hallux dorsiflexion, decreased 
thickness of plantar soft tissue, accentuated hardness/stiffness of the skin, 
and a propensity to develop calluses (82, 96, 101-105). While these 
changes are presumably caused by glycosylation of collagen, their sum 
effect is to enhance plantar pressures in gait. In the presence of 
neuropathy, the accentuated plantar pressures can be implicated in the 
development of ulceration (70, 80, 92, 106). 
 
Mechanisms of Injury 
“The multifactorial etiology of diabetic foot ulcers is evidenced by 
the numerous pathophysiologic pathways that can potentially lead to this 
disorder (24, 43, 54, 62, 90, 107). Among these are two common 
mechanisms by which foot deformity and neuropathy may induce skin 
breakdown in persons with diabetes (69, 108, 109). 
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The first mechanism of injury refers to prolonged low pressure 
over a bony prominence (ie, bunion or hammertoe deformity). This 
generally ca uses wounds over the medial, lateral, and dorsal aspects of 
the forefoot and is associated with tight or ill-fitting shoes. Shoe trauma, 
in concert with loss of protective sensation and concomitant foot 
deformity, is the leading event precipitating foot ulceration in persons 
with diabetes (24, 28, 57, 85).” 
Regions of high pedal pressure are frequently associated with foot 
deformity (68, 73, 76, 77, 106, 107). When an abnormal focus of 
pressure is coupled with lack of protective sensation, the result can be 
development of a callus, blister, and ulcer (110).   The  other  common 
mechanism of ulceration involves prolonged repetitive moderate stress 
(108). This normally occurs on the sole of the foot and is related to 
prominent metatarsal heads, atrophied or anterior- ly displaced fat pads, 
structural deformity of the lower extremity, and prolonged walking. Rigid 
deformities such as hallux valgus, hallux rigidus, hammertoe, Charcot 
arthropathy, and limited range of motion of the ankle (equi- nus), 
subtalar, and MTP joints have been linked to the development of diabetic 
foot ulcers (27, 57, 71, 80, 94, 96).  
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Numerous studies support the significant association between high 
plantar pressures and foot ulceration (26, 70, 80, 92, 106, 111, 112). 
Other biomechanical perturbations, including partial foot amputations, 
have the same adverse effects (57, 68, 80, 113). 
Figure 2 summarizes the various pathways and contribut- ing 
factors leading to diabetic foot complications. 
 
Risk for Infection 
“Infections are common in diabetic patients and are often more 
severe than infections found in nondiabetic patients. Persons with 
diabetes have an increased risk for developing an infection of any kind 
and a several-fold risk for develop- ing osteomyelitis (114). With an 
incidence of 36.5 per 1,000 persons per year, foot infections are among 
the most com- mon lower extremity complications in the diabetic 
population (excluding neuropathy), second only to foot ulcers in 
frequency (115).” 
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“It is well documented that diabetic foot infections are frequently 
polymicrobial in nature (30, 116-121). Hyperglycemia, impaired 
immunologic responses, neuropathy, and peripheral arterial disease are 
the major predisposing factors leading to limb-threatening diabetic foot 
infections (122-124). Uncontrolled diabetes results in impaired ability of 
host leukocytes to fight bacterial pathogens, and ischemia also affects the 
ability to fight infections because delivery of antibiotics to the site of 
infection is impaired.  
Consequently, infection can develop, spread rapidly, and produce 
significant and irreversible tissue damage (125). Even in the presence of 
adequate arterial perfusion, under- lying peripheral sensory neuropathy 
will often allow the progression of infection through continued walking 
or delay in recognition (126, 127).” 
 
Risk for Charcot Joint Disease 
“It has been estimated that less than 1% of persons with diabetes 
will develop Charcot joint disease (128-130). Data on the true incidence 
of neuroarthropathy in diabetes are limited by the paucity of prospective 
or population-based studies in the literature. One large population-based 
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prospective study found an incidence of about 8.5 per 1,000 persons with 
diabetes per year (115); this equates to 0.85% per year and is probably 
the most reliable figure currently available. Much of the data clinicians 
rely upon have been extracted from retrospective studies of small, single-
center cohorts. The incidence of reported Charcot cases is likely to be 
underestimated because many cases go undetected, espe- cially in the 
early stages (131-134).” 
 
“Primary risk factors for this potentially limb-threatening 
deformity are the presence of dense peripheral sensory neu- ropathy, 
normal circulation, and history of preceding trau- ma (often minor in 
nature) (50, 135, 136). Trauma is not limited to injuries such as sprains 
or contusions. Foot deformities, prior amputations, joint infections, or 
surgical trauma may result in sufficient stress that can lead to Charcot 
joint disease (137-140).” 
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Risk for Amputation 
“The reported risk of lower extremity amputations in dia- betic 
patients ranges from 2% to 16%, depending on study design and the 
populations studied (19, 21, 32, 115, 141- 144). LEA rates can be 15 to 
40 times higher among the diabetic versus nondiabetic populations (8, 16, 
34, 35). Although one author suggests that amputation may be a 
marker not only for disease severity but also for disease management, 
it is clear that amputation remains a global problem for all persons with 
diabetes (32, 143). The same risk factors that predispose to ulceration can 
also generally be considered contributing causes of amputation, albeit 
with several modifications (Fig 3).” 
“While peripheral arterial disease may not always be an 
independent risk factor for ulceration when controlling for neuropathy, it 
can be a significant risk factor for amputation (24, 28, 88, 142, 145, 146). 
PAD affecting the feet and legs is present in 8% of adult diabetic patients 
at diagnosis and in 45 % after 20 years (147, 148). The incidence of 
ampu- tation is 4 to 7 times greater for diabetic men and women than 
for their nondiabetic counterparts.  
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Impairment of arte- rial perfusion may be an isolated cause for 
amputation and a predisposing factor for gangrene. Early diagnosis, 
control of risk factors, and medical management as well as timely 
revascularization may aid in avoiding limb loss (30, 52, 77, 88, 149).” 
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Figure 3 The risk factors for amputation are multifactorial and 
similar to those for ulceration. 
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“While infection is not often implicated in the pathway leading to 
ulceration, it is a significant risk factor in the causal pathway to 
amputation (24, 28). Lack of wound heal- ing, systemic sepsis, or 
unresolved infection can lead to extensive tissue necrosis and gangrene, 
requiring amputa- tion to prevent more proximal limb loss. This includes 
soft tissue infection with severe tissue destruction, deep space abscess, or 
osteomyelitis. Adequate debridement may require amputation at some 
level as a means of removing all infected material (77, 123, 150, 151).” 
“Another frequently described risk factor for amputation is chronic 
hyperglycemia. Results of the  Diabetes Control and Complications Trial 
(DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) 
support the long-held theory that chronic poor control of diabetes is 
associated with a host of systemic complications (152, 153). The link 
between degree of glucose control and incidence or pro- gression of 
numerous diabetic complications has been well established by these and 
other studies (154, 155). Such complications include peripheral 
neuropathy, microan- giopathy, microcirculatory disturbances, impaired 
leuko- cyte phagocytosis, and glycosylation of tissue proteins. Each has 
adverse effects on the diabetic foot: They can con- tribute to the etiology 
of foot ulceration, delay normal wound healing, and subsequently lead to 
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amputation (25, 30, 48, 50, 72). Several studies have reported a 
significant correlation  between  elevated  glucose  and  LEA (21, 141,” 
156-161). Amputation has also been associated with other 
diabetes-related comorbidities such as nephropathy, retinopathy, and 
cardiovascular disease (21, 48, 144). Aggressive glucose control, 
management of associated comorbidities, and appropriate lower 
extremity care coordi- nated in a team environment may indeed lower 
overall risk for amputation (30, 90, 162-166). 
“The best predictor of amputation is a history of previous 
amputation. A past history of a lower extremity ulceration or amputation 
increases the risk for further ulceration, infection, and subsequent 
amputation (29, 142, 157, 167). It may also be inferred that patients with 
previous ulceration possess all the risk factors for developing another 
ulcera- tion, having demonstrated that they already have the com- ponent 
elements in the causal pathway (24, 27, 28, 57). Up to 34% of patients 
develop another ulcer within 1 year after healing an index wound, and the 
5-year rate of developing a new ulcer is 70% (164, 168). The recurrence 
rate is high- er for patients with a previous amputation because of abnor- 
mal distribution of plantar pressures and altered osseous architecture. 
The cumulative risks of neuropathy, deformity, high plantar pressure, 
poor glucose control, and male gen- der are all additive factors for pedal 
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ulceration in these dia- betic patients (26, 46, 50, 57, 111). Re-amputation 
can be attributed to disease progression, nonhealing wounds, and 
additional risk factors for limb loss that develop as a result of the first 
amputation.” 
History 
“A thorough medical and foot history must be obtained from the 
patient. The history should address several specific diabetic foot issues 
(Table 2).” 
Physical Examination 
“All patients with diabetes require a pedal inspection whenever 
they present to any health care practitioner,   and 
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they should receive a thorough lower extremity examina- tion at 
least once annually (175). Patients with complaints relating to the 
diabetic foot require more frequent detailed evaluations. The examination 
should be performed system- atically so that important aspects are not 
overlooked (62). It begins with a gross evaluation of the patient and 
extremi- ties. Any obvious problem can then receive closer scrutiny. Key 
components of the foot examination are presented in Table 3. Although 
not specifically mentioned in this sec- tion,  it  is  assumed  that  a  
general  medical     assessment (including vital sign measurements) will 
be obtained.” 
Diagnostic Procedures 
“Diagnostic procedures may be indicated in the assess- ment and 
care of the diabetic foot. Consideration should be given to the following 
tests in concert with those suggested by members of the consulting team. 
It should be noted that many of the following tests lack the ability to 
impart a definitive diagnosis, necessitating clinical correlation.” 
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Laboratory Tests 
“Clinical laboratory tests that may be needed in appropri- ate 
clinical situations include fasting or random blood glu- cose, 
glycohemoglobin (HbA1c), complete blood count (CBC) with or without 
differential, erythrocyte sedimenta- tion rate (ESR), serum chemistries, C-
reactive protein, alka- line phosphatase, wound and blood cultures, and 
urinalysis. Caution must be exercised in the interpretation of laborato- ry 
tests in these patients, because several reports have doc- umented the 
absence of leukocytosis in the presence of severe foot infections (117, 
122, 151, 176-178). A common sign of persistent infection is recalcitrant 
hyperglycemia despite usual antihyperglycemic regimens (150).” 
 
Imaging Studies 
“The diabetic foot may be predisposed to both common and 
unusual infectious or noninfectious processes, partially because of the 
complex nature of diabetes and its associat- ed vascular and neuropathic 
complications. As a result, imaging presentations will vary due to lack of 
specificity in complex clinical circumstances (179-181). Such variability 
creates a challenge in the interpretation of imaging studies. Therefore, 
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imaging studies should only be ordered to estab- lish or confirm a 
suspected diagnosis and/or direct patient management. Distinguishing 
osteomyelitis from aseptic neuropathic arthropathy is not easy, and all 
imaging studies (Fig 4) must be interpreted in conjunction with the 
clinical findings (123, 151).” 
“Plain radiographs should be the initial imaging study in diabetic 
patients with signs and symptoms of a diabetic foot disorder (180, 182).” 
“Radiographs can detect osteomyelitis, osteolysis, fractures, 
dislocations seen in neuropathic arthropathy, medial arterial calcification, 
soft tissue gas, and foreign bodies as well as structural foot deformities, 
pres- ence of arthritis, and biomechanical alterations (183). Acute 
osteomyelitis might not demonstrate osseous changes for up to 14 days. 
Serial radiographs should be obtained in the face of an initial negative 
radiographic image and a high clinical suspicion of osseous disease (117, 
123).” 
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“Technetium-99 methylene diphosphonate (Tc-99 MDP) bone 
scans are often used in diabetic foot infection to deter- mine the presence 
of osteomyelitis. Although highly sensi- tive, this modality lacks 
specificity in the neuropathic foot (184, 185). Osteomyelitis, fractures, 
arthritis, and neuro- pathic arthropathy will all demonstrate increased 
radiotrac- er uptake. However, a negative bone scan is strong evidence 
against the presence of infection. To improve the specifici- ty of nuclear 
imaging, white blood cells can be labeled with Tc-99 
hexamethylpropyleneamineoxime (Tc-99 HMPAO), indium-111 oxime, 
or gallium-67 citrate (179, 186-189).” 
“Indium-111 selectively labels polymorphonuclear leuko- cytes 
and is more specific for acute infections than Tc-99 MDP scanning. 
Chronic infections and inflammation are not well imaged with indium-
111, because chronic inflam- matory cells (ie, lymphocytes) predominate 
and are not well labeled with indium. Combining Tc-99 MDP and 
indium- 111 increases the specificity of diagnosing osteomyelitis (190). 
This combined technique is useful, because the Tc-99 MDP scan localizes 
the anatomic site of inflammation and the indium-111 labels the 
infected bone (180, 191).  
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The indium-111 scan is not typically positive in aseptic neuro- 
pathic arthropathy, although false-positive indium scans can occur (192-
194). A 100% sensitivity and 89% specificity have been reported with the 
combined technique in evaluat- ing diabetic infections (190, 191, 195).” 
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Vascular Evaluation 
“The lower extremity must be assessed for vascular and 
neuropathic risk factors. Although positive findings in the neurologic 
examination rarely require further evaluation, positive findings of 
vascular insufficiency may require fur- ther consultation. The indications 
for vascular consultation include an ankle brachial index of less than 0.7, 
toe blood pressures less than 40 mmHg, or transcutaneous oxygen tension 
(TcPO2) levels less than 30 mmHg, since these measures of arterial 
perfusion are associated with impaired wound healing (27, 47, 87, 90, 
212, 213).” 
“If the history and physical examination suggest ischemia (ie, 
absent pedal pulses) or if a nonhealing ulcer is present, further evaluation 
in the form of noninvasive testing is war- ranted.” 
“Noninvasive arterial studies should be performed to determine 
lower extremity perfusion. Such studies may include Doppler segmental 
arterial pressures and waveform analysis, ankle-brachial indices (ABI), 
toe blood pressures, and TcPO2 (89, 214, 215). Ankle-brachial indices 
may be misleading, because ankle pressures can be falsely elevated due 
to medial arterial calcinosis and noncompressibility of affected arteries 
(52, 216, 217).  
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A growing body evidence suggests that toe blood pressures in 
diabetic patients may have a role in predicting foot ulceration risk as well 
as pre- dicting successful wound healing (213, 218, 219). TcPO2 
measurements have received similar support in the litera- ture (47, 87, 
212). Although not consistently predictive of wound healing outcomes, 
these physiologic measures of tis- sue oxygenation are highly predictive 
of wound healing failure at levels below 25 mmHg (87, 212, 220). Both 
tests can be performed distally on the foot regardless of arterial 
calcification in the major pedal arteries, and they are both favorable at 
pressures in the range of 40 mmHg (90, 212, 213).” 
“Laser Doppler velocimetry and measurement of skin perfusion 
pressure (SPP) have primarily been used in research settings, but can 
accurately assess blood flow and oxygen tension in the superficial 
arterioles and capillaries of the skin (220-225). Several recent reports 
indicate that laser Doppler measurement of SPP can be highly predictive 
of critical limb ischemia and wound healing failure at levels less than 30 
mmHg (223, 224).” 
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“Vascular consultation should be considered in the presence of 
abnormal noninvasive arterial studies or a nonheal- ing ulceration (30, 
54, 173, 215, 226). Arteriography with clearly visualized distal runoff 
allows appropriate assess- ment for potential revascularization (227-229). 
Magnetic resonance angiography (230) or CT angiogram are alterna- 
tives for evaluation of distal arterial perfusion (229, 231). 
Neurologic Evaluation 
“Peripheral sensory neuropathy is the major risk factor for diabetic 
foot ulceration (24, 26, 27, 46, 50). The patient his- tory and physical 
examination utilizing the 5.07 Semmes- Weinstein monofilament (10-g) 
wire are sufficient to identi- fy individuals at risk for ulceration (26, 232-
235).” 
“Vibration perception threshold assessment with the bioth- 
esiometer is also useful in identifying patients at high risk for ulceration 
(44, 57, 236). More  sophisticated studies such as nerve conduction 
studies are rarely necessary to diagnose peripheral sensory neuropathy. 
Patients with neu- ropathic ulcerations usually have such profound 
sensory neuropathy that these studies add little to their clinical 
management (49).” 
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Plantar Foot Pressure Assessment 
“High plantar foot pressure is a significant risk factor for 
ulceration (26, 45, 59, 70, 76, 80, 237). Measurement of high plantar 
foot pressure is possible utilizing a variety of modalities. Several 
computerized systems can provide quantitative measurement of plantar 
foot pressure (76, 81, 238-241). While these measurements may be 
important in identifying areas of the foot at risk for ulceration and possi- 
bly in evaluating orthotic adjustments (57, 59), they are pri- marily used 
in diabetic foot research. The Harris mat, while not as sophisticated, can 
provide a qualitative measurement of plantar foot pressures and can 
identify potentially vulner- able areas for ulceration.(242).” 
Evaluation of Ulcers 
“The initial evaluation of the diabetic foot ulcer must be 
comprehensive and systematic to ascertain the parameters that might 
have led to its onset as well as determine the presence of factors that 
can impair wound healing (25, 52, 54). Critical in this regard are 
assessments for vascular per- fusion (ischemia), infection/osteomyelitis, 
and neuropathy. As previously discussed, a thorough vascular evaluation 
must be performed; this includes palpation of pulses, clini- cal evaluation 
of capillary filling time, venous filling time, pallor on elevation, and 
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dependent rubor (283). If pulses are not palpable or if clinical findings 
suggest ischemia, nonin- vasive arterial evaluation (eg, segmental 
Doppler pressures with waveforms, ankle brachial indices, toe pressures, 
TcPO2 measurements) and vascular surgical consultation are warranted. 
When required, these physiologic and anatomic data can be 
supplemented with the use of magnet- ic resonance angiography (230) or 
CT angiography (CTA) and subsequent use of arteriography with digital 
subtraction angiography (DSA) as necessary (77, 89, 284).” 
Classification of Diabetic Ulcers 
“Appropriate classification of the foot wound is based on a 
thorough assessment. Classification should facilitate treat- ment and be 
generally predictive of expected outcomes. Several systems of ulcer 
classification are currently in use in the US and abroad to describe these 
lesions and commu- nicate severity (62, 90, 288-292). Perhaps the easiest 
system is to classify lesions as neuropathic, ischemic, or neuro- 
ischemic, with descriptors of wound size, depth, and infec- tion (90). 
Regardless of which system is used, the clinician must be able to easily 
categorize the wound and, once clas- sified, the ensuing treatment should 
be directed by the underlying severity of pathology.” 
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“Although no single system has been universally adopted, the 
classification system most often used was described and popularized by 
Wagner (292). In the Wagner system foot lesions are divided into six 
grades based on the depth of the wound and extent of tissue necrosis 
the University of Texas San Antonio (UTSA) sys- tem  associates 
lesion depth with both ischemia and infection (290). This system has 
been validated and is generally predictive of outcome, since increasing 
grade and stage of wounds are less likely to heal without revascular- 
ization or amputation (290, 293). The UTSA system is now widely used 
in many clinical trials and diabetic foot centers.” 
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Figure  Assessment of a diabetic foot ulcer includes not only a 
description of the skin lesion but also the find- ings necessary for accu- 
rate assessment of the contributing factors and etiology. 
 
 
 
 
 
 
 
 
 
Tissue Management / Wound Bed Preparation 
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Debridement.  
“Debridement of necrotic tissue is an inte- gral component in the 
treatment of chronic wounds since they will not heal in the presence of 
unviable tissue, debris, or critical colonization (314, 315). Undermined 
tissue or closed wound spaces will otherwise harbor bacterial growth 
(312, 316, 317). Debridement serves various functions: removal of 
necrotic tissue and callus; reduction of pressure; evaluation of the wound 
bed; evaluation of tracking and tunneling; and reduction of bacterial 
burden (318, 319). Debridement facilitates drainage and stimulates 
healing (320). However, debridement may be contraindicated in arterial 
ulcers (321). Additionally, except in avascular cases, adequate 
debridement must always precede the application of topical wound 
healing agents, dressings, or wound clo- sure procedures (30, 288, 322, 
323). Of the five types of debridement (surgical, enzymatic, autolytic, 
mechanical, biological), only surgical debridement has been proven to be 
efficacious in clinical trials (323).” 
Surgical debridement. “Surgical debridement is the cor- nerstone 
of management of diabetic foot ulcers. Thorough sharp debridement of 
all nonviable soft tissue and bone from the open wound is accomplished 
primarily with a scalpel, tissue nippers, curettes, and curved scissors 
(324). Excision of necrotic tissue extends as deeply and proximally as 
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necessary until healthy, bleeding soft tissue and bone are encountered. 
Any callus tissue surrounding the ulcer must also be removed. The main 
purpose of surgical debridement is to turn a chronic ulcer into an acute, 
healing wound (325). A diabetic ulcer associated with a deep abscess 
requires hospital admission and immediate incision and drainage (178). 
Joint resection or partial amputation of the foot is necessary if 
osteomyelitis, joint infection, or gan- grene are present (41, 100, 123, 151, 
180, 271).When surgical or sharp debridement is not indicated, other 
types of debridement can be used. For example, vas- cular wounds may 
benefit from enzymatic debridement, while an extremely painful wound 
may benefit from autolytic debridement. Mechanical debridement is 
often used to cleanse wounds prior to surgical or sharp debride- ment. In 
areas where the medical staff is not trained in sur- gical or sharp 
debridement, these other forms of debride- ment may be useful (325).” 
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Figure  “New technologies have been developed that have 
proved useful  for management of diabetic ulcerations. (A)Platelet-rich 
plasma (PRP) involves use of the patient’s blood, which is collected and 
then fractionated through centrifuga- tion. A platelet-rich and platelet-
poor supernatant remains. (B) This case involved use of autologous 
platelet-rich plasma gel activated with thrombin and placed onto a 
healthy wound bed. (C) The platelet gel or clot may also be covered with 
a synthetic skin graft  substitute.” 
An Infra Malleolar infection occurring in a Diabetic patient is 
characterised as a Diabetic foot Infection. (1) 
Every 30 second, a leg is lost because of DM. These ulcers tend to 
heal slowly, need intensive care and healing can be complicated by 
infection and gangrene, leading to long-term in-hospital treatment and/or 
amputation. (4) 
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Moreover, foot ulcers have major negative effects on quality of 
life, due to loss of mobility, loss of work and reduction of social activities 
(4), one study has demonstrated that quality of life of diabetic foot ulcer 
patients was comparable to that of patients with recurrent breast 
cancer(5).  
Despite these poor outcomes, the feet of diabetic patients have 
traditionally received relatively little attention from health care workers 
and scientists. (6) 
However, in recent decades our knowledge on diabetic foot ulcers 
has increased, with a rise in the number of scientific publications and the 
production of guidelines on prevention and management. (6, 7, 8) 
Hospitalization, surgical procedures, and prolonged/broad-
spectrum antibiotic therapy may predispose diabetic patients to become 
colonized and/or infected with antibiotic-resistant organisms such as 
Methicillin-Resistant Staphylococcus aureus (MRSA) or vancomycin-
resistant enterococci (VRE). (1) 
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CLASSIFICATION 
IWGDF (PEDIS) and IDSA. IWGDF developed a system for 
classifying diabetic foot wounds that uses the acronym PEDIS, which 
stands for perfusion, extent (size), depth (tissue loss), infection, sensation 
(neuropathy). While originally developed as a research tool (11), it offers 
a semiquantitative gradation for the severity of each of the categories. 
The infection part of the classification differs only in small details from 
the classification developed by IDSA. Major advantages of both 
classifications are clear definitions and a relatively small number of 
categories, making them more user-friendly for clinicians having less 
experience with diabetic foot management. Importantly, the IDSA 
classification has been prospectively validated (12, 13, 14) as predicting 
the need for hospitalization (in one study, 0 for no infection, 4% for mild, 
52% for moderate, and 89% for severe infection) and for limb amputation 
(3% for no infection, 3% for mild, 46% for moderate, and 70% for severe 
infection) (13). 
Wagner—Wagner, in collaboration with Meggitt, developed perhaps the 
first, and still among the most widely used, classification schemes for 
diabetic foot wounds (2, 15). It assesses ulcer depth and the presence of 
infection and gangrene with grades ranging from 0 (pre- or post-
ulcerative) to 5 (gangrene of the entire foot). The system only deals 
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explicitly with infections of all types (deep wound abscess, joint sepsis, 
or osteomyelitis) in grade 3. 
S(AD)/SAD—This is an acronym for 5 key points of foot ulcers: size, 
(area, depth), sepsis (infection), arteriopathy, and denervation (3). Each 
point has 4 grades, thus creating a semi-quantitative scale. Infection is 
graded as none, surface only, cellulitis, and osteomyelitis; these are not 
further defined. One study reported good inter- observer agreement. 
Unlike the other key points, studies have not shown infection to be 
related to outcome of the foot ulcer (3, 16). 
The SINBAD ulcer classification is a simplified version of the 
S(AD)/SAD system with a decreased number of grades of infection 
(present or absent) (17).  
University of Texas (UT) ulcer classification (18)—This system has a 
combined matrix of 4 grades (related to the depth of the wound) and 4 
stages (related to the presence or absence of infection or ischemia). The 
classification successfully predicted a correlation of the likelihood of 
complications in patients with higher score. 
Ulcer Severity Index [49]—This index measures 20 clinical parameters 
and allows determination of an infection score by combining the scores 
for erythema, edema, and purulence, while counting exposed bone 
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separately. In 1 study, presence or absence of infection in this index was 
not associated with a difference in wound healing (19).   
Diabetic Ulcer Severity Score (DUSS) and MAID (20, 21)—These 
scoring systems are based on specific wound characteristics associated 
with stages of wound repair. Studies have found no significant correlation 
between soft tissue infections and wound healing, although there was a 
trend toward more infection in the higher-risk groups (20, 21).  
DFI Wound Score (22)—Lipsky et al developed this 10- item scoring 
system to measure outcomes in studies of various antimicrobial 
treatments for DFIs. The score consists of a semi quantitative assessment 
of the presence of signs of inflammation, combined with measurements of 
wound size and depth. Explicit definitions allow numerical scoring of 
wound parameters. An evaluation of the wound score calculated for 371 
patients with DFI demonstrated that it significantly correlated with the 
clinical response and that scores demonstrated good internal consistency 
(22). Patients with more severe wounds had higher scores; clinical 
response was favourable at the follow-up assessment in 94.8% with a 
baseline score <12 compared with 77.0% with a score >19. Surprisingly, 
excluding scores for wound discharge (purulent and non-purulent), 
leaving an 8-item score, provided better measurement statistics (22).  
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 The DFI Wound Score appears to be a useful tool for predicting 
clinical outcomes in treatment trials, but its complexity requires clinicians 
to use a scoring sheet (22). 
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Table 3: DFI Wound Score 
 
 
 
 
50  
BACTERIOLOGY 
Aerobic, Gram-positive cocci are the predominant organisms 
responsible for acute DFI, with Staphylococcus aureus the most 
commonly isolated pathogen (1, 9, and 10). 
In wounds that are chronic, especially in patients who have recently 
been treated with antimicrobial therapy, infections are more frequently 
polymicrobial and the causative pathogens are more diverse, often 
including aerobic gram-negative bacilli and obligate anaerobic bacteria 
(1, 10) 
• Staphylococcus aureus  
They are gram positive, non-motile, non sporing facultative anaerobes 
arranged in clusters. They grow readily in ordinary culture media 
under aerobic or anaerobic conditions with a temperature range of 10-
42 C. (23) On Nutrient Agar, the colonies are circular convex, smooth, 
opaque and Golden Yellow. 
• On Blood Agar, the colonies are similar and most strains are Beta 
Haemolytic. 
• On Mac Conkey’s medium, colonies are smaller and pink due to 
lactose fermentation. (24)  
• They produce toxins like haemolysins, leucocidins, enterotoxins, 
exfoliative toxin and coagulase. (25, 26) 
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• Direct microscopy shows gram positive cocci in clusters 
Culture is diagnostic and colonies are smooth, circular and vary in size 
from 1 to 4 mm depending on the strain and medium used. (23)  
Most isolates are resistant to Benzyl Penicillin by production of 
Pencillinase. For broad spectrum penicillins, 20% of strains show 
resistance by Beta Lactamase production, by the presence of mecA 
gene. Newer drugs like Vancomycin and Teicoplanin are often 
needed. (27) 
 
 
Fig 1: Staphylococci- Gram Staining 
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METHODOLOGY AND MATERIALS 
 This study was conducted in the Institute of General 
Surgery, RGGGH. The Institute receives large number of diabetic foot 
patients. In that 50 patients were included in the study between July 2016 
to September 2016. Patients with Chronic Diabetic Foot and previous 
amputations were also included in the study. Patients were recruited from 
the surgical OPD and admitted. Data were collected by detailed history, 
clinical examination, wound or ulcer and were recorded in the pre-
designed profoma. Age, sex, socioeconomic status, duration and type of 
diabetes, wagner’s classification,university of texas scoring examination 
findings, blood investigations, renal function test, swab of  the wound. X-
ray and treatment provided were collected. At presentation, the site of the 
ulcer was noted, and a photograph was taken. After wound debridement, 
the area of each ulcer was measured using a wound-mapping chart . Each 
ulcer was graded using both classification systems and staged using the 
UT system. Ulcers were labeled infected if a purulent discharge was 
present with two other local signs (warmth, erythema, lymphangitis, 
lymphadenopathy, oedema, pain). Wound depth was evaluated using a 
sterile blunt probe. The ability to probe to bone (20) with the presence of 
local or systemic infection and suggestive radiological features provided 
a clinical diagnosis of osteomyelitis. The diagnosis of lowerextremity 
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vascular insufficiency was made clinically on the basis of absence of both 
pedal pulses of the involved foot and/or an ankle-brachial pressure index 
of 0.9 (21). Patients initially were seen in the diabetic foot clinic on a 
weekly basis and were provided with the best possible care for their 
ulcers at each visit. To remove extensive callus and necrotic tissue, 
wound debridement was performed. After wound dressing, pressure relief 
was provided with either a scotchcast boot or a total contact cast. Broad 
spectrum antibiotics were prescribed if ulcers showed clinical signs of 
infection (growth factors were not used to enhance healing in this study). 
Patients with cl clinical evidence of ischemia had noninvasive ultrasound 
vascular studies and were seen by the vascular surgeon if necessary. 
Patient follow-up was part of the normal treatment. Unhealed ulcers were 
followed up for a minimum period of 6 months. Once a patient’s ulcer 
had healed completely or a lower-limb amputation was performed, the 
outcome was noted and the patient was deemed to have completed the 
study 
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Statistical analysis; 
A chi square test was used to assess the trend association between 
increasing grade or stage and the prevalence of lower-extremity 
amputation (25,25a). To assess the potential association between stage 
and the number of amputations performed by the end of the study period, 
chi square  analysis with odds ratio (OR) was performed. Kaplan-Meier 
survival analysis was used to estimate median healing times, and a log-
rank test was used to compare healing times for different levels of grade 
or stage. Cox regression analysis was used to assess the ability of grade 
and stage to predict healing within the study period (25,25a). The 95% CI 
was calculated whenever appropriate, and statistical significance was 
defined as a P value 0.05. Statistical analysis was performed using SPSS 
for Windows, version 9.0 (SPSS, Chicago). 
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RESULTS 
 Table 1 – Sociodemographic characteristics of the patients 
Characteristics Number  %age 
Age/years   
<40 1 2% 
41-50 21 42% 
51-60 19 38% 
>60 9 19% 
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AGE DISTRIBUTION
<40
41-50
51-60
>60
 
 
 
 
 
 
 
 
 
59  
Sex Number % 
Male 33 66 
Female 17 34 
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Characteristics Number % 
Type of diabetes   
Type I  0 0 
Type II  50 100 
Socioeconomic status   
Lower 7 14 
Middle 30 60 
Upper 13 26 
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UNIVERSITY OF TEXAS CLASSIFICATION SYSTEM 
Stage Grade n No of Amputations 
A 1 19 0 
A 2 2 0 
A 3 3 0 
B 1 3 0 
B 2 3 1 
B 3 5 2 
C 1 7 1 
C 2 1 0 
C 3 1 1 
D 1 3 1 
D 2 2 1 
D 3 1 1 
 
64  
 
 
0
2
4
6
8
10
12
14
16
18
20
Stage A Stage B Stage C Stage D
University of Texas Score - Distribution
Grade 1 Grade 2 Grade 3
65  
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
Stage A Stage B Stage C Stage D
University of Texas - Amputation Distribution
Grade 1 Grade 2 Grade 3
66  
 Table 5- Culture report 
Investigations No.of patients % 
Culture   
Staph.aureus  
 
11 22 
Mixed 19 38 
Others 20 40 
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Diabetes is associated with complications in its long run. Foot 
infection and subsequent amputation of a lower extremity are one of the 
most common reason for hospitalisation. As observed in our study, it is 
more common in males ( n 33). More common age group is between 40-
60 in our study. The hallmark of diabetic foot is its gross infection and 
major contributing factors for late presentation are poor knowledge about 
the disease, undetected diabetes, trust in faith healers, bare foot gait.  
Peripheral neuropathy and infection are common risk factors 
diabetic foot. In our study mixred infection( n 19), includes aerobes, 
anaerobes, is common. 
Four patients died of sepsis(n=3) and chronic renal failure(n=1) 
Of all patients, 15% had lower-limb amputations as a result of their 
nonhealing ulcers, 65% had ulcers that healed completely, 4% (three  
patients) died, and the remaining 16% had ulcers that still had not healed 
at study termination, despite a minimum follow-up period of 6 months 
Wagner grade showed a significant positive trend with increased number 
of amputations (x2 trend = 21.0, P 0.0001). This was also true for both 
grade (x2 trend = 23.7, P 0.0001) and stage (x2 trend = 15.1, P = 0.0001) 
of the UT system. Using the UT stage, patients were 11 times more likely 
to undergo a lower-limb amputation if their ulcers were infected (stage B) 
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when compared with clean nonischemic ulcers (stage A) (27.5 vs. 3.3%, 
P 0.0001, OR = 11.1, 95% CI 3.0–41.0). Patients with noninfected 
ischemic ulcers (stage C) were five times more likely to undergo a lower-
limb amputation when compared with stage A ulcers, but this did not 
reach statistical significance (13.6 vs. 3.3%, P = 0.09, OR = 4.6, 95% CI 
0.9–24.7). However, when ischemic ulcers (with or without infection) 
were combined, patients with ischemic ulcers (stages C and D) were three 
times more likely to undergo amputation when compared with patients 
with nonischemic (stages A and B) ulcers (32.5 vs. 14.7%, P 0.05, OR = 
2.8, 2 = 6.1, 95% CI 1.2–6.5). Patients with a combination of infection 
and ischemia (stage D) were 15 times more likely to undergo a lower-
limb amputation when compared with patients with clean nonischemic 
ulcers (stage A) (33.3 vs. 3.3%, P 0.0001, x2 = 21.2, OR = 14.7, 95% CI 
3.7–58.2). Grade for the Wagner (r = 0.26, P 0.01) and UT (r = 0.26, P 
0.01) systems both showed a weak positive correlation with ulcer healing 
time for the 65% of patients whose ulcers healed completely, but stage 
did not (r = 0.06, P = 0.48).  
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Kaplan-Meier survival analysis showed no significant difference 
between median healing times in grades 1, 2, and 3 of the Wagner system 
(8, 16, and 11 weeks, respectively) (x2 = 5.68, df = 3, P = 0.13) or 
median healing times in grades 1, 2, and 3 of the UT system (8, 12 and 16 
weeks, respectively) (x2 = 5.47, df = 2, P = 0.07). However, analysis 
showed that the median healing times (7, 11, 16, and 20 weeks) increased 
with each stage of the UT system (x2 = 10.24, df = 3, P = 0.02). 
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DISCUSSION 
Data on the burden of diabetes-related complications from 
developing countries are relatively rare and comparisons between them 
are made difficult by differing degrees of population selection and by the 
use of different clinical methods (23). Despite a number of local 
initiatives to improve access to foot care, the vast majority of people with 
diabetes in developing countries do not have access The report by the 
Centers for Disease Control and Prevention (CDC) on geographic 
disparities in diabetes-related amputations on the Texas–Mexico border 
reported that incidence of diabetes-related amputations of lower extremity 
in this area was nearly double the rate of non-border countries (25). Wide 
differences between other centres have also been reported (10). In order 
to identify the reasons for such differences, it is necessary to compare the 
outcomes of clinical care in different populations, both between centres 
and between countries, and this requires careful definition of the 
populations selected for the study.  
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“Wagner’s Classification for diabetic foot disease (adopted from 
Levin and O’Neals)” 
Grade Description 
Grade 0 High risk foot and no ulceration 
Grade 1 Superficial Ulcer; Total destruction 
of the thickness of the skin  
Grade 2 Deep Ulcer (cellulitis); Penetrates 
through skin,fat,ligaments not 
affecting bone 
Grade 3 Osteomyelitis with Ulceration or 
abscess 
Grade 4 Gangrenous patches limited to toes 
or part of the foot 
Grade 5 Gangrene of the entire foot  
 
 
 
73  
A robust system of ulcer classification is necessary for this 
purpose. A number of groups have used classification schemes to seek 
associations between baseline variables and clinical outcome, but the 
results have been inconsistent. Armstrong and colleagues (16) reported a 
significant association between outcome and ulcers of increasing depth 
(UT grade), and especially in the presence of ischaemia, infection or both 
(UT stage). This study was limited, however, in using just a linear-by-
linear association for analysis, and by the use of amputation (which 
should properly be regarded as a treatment rather than a clinical 
endpoint), as the single outcome measure. This could have influenced the 
results if, for instance, amputation was established as the treatment of 
choice for certain types of lesion, such as osteomyelitis (10). 
A close association was later shown between the results of the UT 
system and the earlier Wagner classification (26). In contrast to the report 
by Armstrong et al.(16), however, Treece and colleagues (18) found no 
association between infection and any outcome measure (healing, non-
healing, amputation, death), although differences were observed between 
ulcer area, depth and the presence or not of peripheral arterial disease 
(PAD). The same group has recently confirmed these findings, reporting 
that the dominant factors influencing healing in a UK population were 
ulcer area and the presence of ischaemia (27). 
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Few longitudinal studies have assessed the power of a foot ulcer 
classification system in predicting clinical outcome. The results of the 
study revealed that grade and stage affect the outcome of diabetic foot 
ulcers. The higher the grade, the greater the number of amputations 
performed. The trend for the UT grade was slightly greater than that for 
the Wagner grade. As for stage, the presence of infection and/or ischemia 
increased the risk of amputation. Because of small numbers of patients in 
each group, the increased amputation risk seen with stage C did not reach 
statistical significance, but when regrouped, patients with ischemia 
(stages C and D) had higher risk of amputation compared with patients 
without ischemia (stages A and B). Previous studies have shown that 
infection and peripheral vascular disease are associated with an increased 
risk of amputation (26,27). In addition, only stage both showed a positive 
relationship with time to healing and predicted healing within the study 
period. It should be noted, however, that grading and staging were done 
at presentation only. Some patients may have had recurrent wound 
infection, which would prolong wound healing, and a few patients had 
revascularization procedures, which enhance wound healing.  
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The HbA1c level was not measured for all patients at presentation 
or at the same time point and therefore was not used for analysis. 
Additionally, only 6% of patients underwent revascularization before the 
end of the study. These confounding factors may have altered or 
undermined the expected effects of grade and stage at baseline on 
amputation rates and healing time Wagner grade 4 and 5 ulcers were 
poorly represented in this study group, making it impossible to say if 
grades 4 and 5 add extra predictive power to the wound classification 
system. Gangrene is present in grades 4 and 5 and is usually due to a 
combination of ischemia and infection; these grades will, in most cases, 
have a similar outcome. Further studies are necessary to compare clinical 
outcomes of Wagner grade 4 and 5 ulcers with that of UT grade 3, stage 
D—an argument that makes the UT system appear simpler and more 
practical. An infected ischemic ulcer that penetrates to tendon (grade 2, 
stage D, or, simply, grade 2D of the UT system) alternatively will be 
grade 2 of the Wagner system. A labeling of grade 2 of the Wagner 
system thus will not alert other members of the foot care team of the 
presence of infection and ischemia, which can prolong wound healing 
and increase the risk of lower-limb amputation. The addition of stage to 
grade improves the descriptive and predictive power of a wound 
classification system, especially for ulcers within the same grade.  
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The UT system, which combines grade and stage, is more 
descriptive and shows a greater association with increased risk of 
amputation and prediction of ulcer healing when compared with the 
Wagner system. Therefore, for groups rather than individual patients, the 
UT system, which is simple and easy to use, is a better predictor of 
clinical outcome., 
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CONCLUSION 
Diabetic foot and its complications are troublesome, source 
consuming and producing disability, morbidity and mortality. — 
Increasing stage, regardless of grade, is associated with increased risk of 
amputation and prolonged ulcer healing time. The UT system’s inclusion 
of stage makes it a better predictor of outcome 
Prevention is the best treatment 
Grading of the diabetec foot lesions according to Wagner’s 
classification helps in choosing appropriate treatment to the grade. Patient 
education and strict glycemic control can reduce the burden of diabetic 
foot. Early diagnosis and hospitalization, appropriate treatment including 
medical and surgical treatment according to the grade can reduce the 
morbidity mortality and improve the outcome of the disease 
 
 
 
 
 
 Key to master chart  
 
Sex – M-Male; F-female 
Type - type of diabetes – I;II 
Culture- Mx-mixed organisms; S- stap.aureus alone 
“Wagner’s Classification for diabetic foot disease (adopted from Levin and 
O’Neals)”- 
Grade Description 
Grade 0 High risk foot and no ulceration 
Grade 1 Superficial Ulcer; Total destruction of the 
thickness of the skin  
Grade 2 Deep Ulcer (cellulitis); Penetrates through 
skin,fat,ligaments not affecting bone 
Grade 3 Osteomyelitis with Ulceration or abscess 
Grade 4 Gangrenous patches limited to toes or part 
of the foot 
Grade 5 Gangrene of the entire foot  
 
Treatment- A-antibiotics;Amp-amputation (of any type);D-debridment;I&D- incision 
and drainage 
Rft- renal function test ; Ab-abnormal; N-normal 
Mortality- yes;no Cause- Sep-Sepsis; DKA-Diabetic Ketoacidosis; CRF- Chronic 
Renal Failure 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 DATA COLLECTION SHEET 
 
I.Patient particulars:   
Name                                       DOA                                  Case No. 
Age                                           DOS                                    I.p.No. 
Sex                                           DOD                                   Address 
Occupation: 
II.Diagnosis 
III.Chief complaints   (with duration) 
A.Ulcer 
B.Discharge 
C.Other complaints 
PAST HISTORY: 
HISTORY OF PREVIOUS OPERATION - 
DURATION OF DIABETES  - 
OTHER COMPLICATIONS OF DIABETES 
PERSONAL HISTORY: 
EXAMINATION: 
INVESTIGATIONS: 
MANAGEMENT: 
Operated /Non operated- 
 
 
 
 
 
 
 POST OPERATIVE COURSE: 
      Recovery -  
      Complications - 
 
FOLLOW UP: 
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 Master chart 
S.No Name Age Sex Type Culture Wagner 
Score 
Univ 
of 
Texas 
Score 
Treatment RFT Mortality/ 
Cause 
1 RAVI 40 M 2 MX 1 A1 DEB N NO 
2 RAJESH 56 M 2 S 2 B2 DEB N NO 
3 ELUMALAI 67 M 2  3 B3 AMP N NO 
4 MURUGAN 45 M 2  2 D2 DEB N NO 
5 GOBINATH 55 M 2 MX 3 B3 DEB N NO 
6 NAGENDRAN 51 M 2  1 D1 DEB N NO 
7 MARIMUTHU 47 M 2 S 1 D1 DEB N NO 
8 NATARJAN 49 M 2 S 1 B1 DEB N NO 
9 JOSEPH 76 M 2 S 4 D3 AMP A Yes/Sepsis 
10 GABRIEL 65 M 2  3 B3 DEB N NO 
11 MOOSA 44 M 2 MX 1 C1 AMP N NO 
12 MOHAMMED 54 M 2 MX 1 B1 DEB N NO 
13 FAROOQ 48 M 2 MX 1 B1 DEB N NO 
14 GOPALAN 43 M 2  2 B2 DEB N NO 
15 RAJARAJAN 55 M 2 MX 1 C1 DEB N NO 
16 RAJENDRAN 58 M 2 S 3 A3 DEB N NO 
17 KANGEYAN 41 M 2 MX 1 C1 DEB N NO 
18 KESAVAN 42 M 2  2 C2 A N NO 
19 KATHIRAVAN 52 M 2 S 1 A1 DEB N NO 
20 IYYAPAN 51 M 2 MX 1 C1 DEB N NO 
21 SILAMBARASAN 60 M 2 MX 3 B3 DEB N NO 
22 MAARI 46 M 2  1 C1 DEB N NO 
23 SONAMUTHU 44 M 2 S 1 A1 DEB N NO 
24 MALAIYANDI 39 M 2  1 C1 A N NO 
25 MARUDHAMALAI 65 M 2  3 A3 DEB N NO 
26 UTHIRAKUMAR 59 M 2 MX 3 B3 AMP A YES/SEPSI
S 
 27 THIRUSELVAN 55 M 2  2 B2 AMP A NO 
28 KUBERAN 44 M 2  1 A1 A N NO 
29 MADHAN 49 M 2 MX 2 A2 DEB N NO 
30 SATHYAMOORTHY 48 M 2  1 A1 A N NO 
31 ROSAIYA 55 M 2  1 C1 DEB N NO 
32 KULASEKARAN 58 M 2 MX 3 A3 DEB N NO 
33 VEERAIYAN 43 M 2  1 A1 A N NO 
34 RAJALAKSHMI 56 F 2  1 A1 DEB N NO 
35 ESWARI 67 F 2 MX 3 C3 AMP N YES/CRF 
36 RAJI 45 F 2 S 1 A1 A N NO 
37 SULTHANA 56 F 2  2 A2 DEB N NO 
38 MARIYAMMAL 54 F 2 MX 1 A1 A N NO 
39 ELLAMAL 43 F 2 MX 1 A1 DEB N NO 
40 ANJALAI 41 F 2  1 A1 A N NO 
41 MARY 65 F 2 MX 2 D2 AMP N NO 
42 LAKSHMI 78 F 2 S 1 B1 AMP A NO 
43 NACHIYAR 55 F 2  1 A1 A N NO 
44 RAKKAMAL 54 F 2 MX 1 A1 DEB N NO 
45 ROSY 46 F 2 S 1 A1 A N NO 
46 PARAMESHWARI 55 F 2  1 A1 DEB N NO 
47 SUNDARI 43 F 2 S 1 A1 A N NO 
48 VISALATCHI 45 F 2  1 A1 DEB N NO 
49 MURUGESHWARI 56 F 2 MX 1 A1 DEB N NO 
50 REKHA 77 F  MX 1 D1 AMP A YES/SEPSI
S 
 
 
 
 
 
 
 
Key to master chart  
 
Sex – M-Male; F-female 
Type - type of diabetes – I;II 
Culture- Mx-mixed organisms; S- stap.aureus alone 
“Wagner’s Classification for diabetic foot disease (adopted from Levin and 
O’Neals)”- 
Grade Description 
Grade 0 High risk foot and no ulceration 
Grade 1 Superficial Ulcer; Total destruction of the 
thickness of the skin  
Grade 2 Deep Ulcer (cellulitis); Penetrates through 
skin,fat,ligaments not affecting bone 
Grade 3 Osteomyelitis with Ulceration or abscess 
Grade 4 Gangrenous patches limited to toes or part 
of the foot 
Grade 5 Gangrene of the entire foot  
 
Treatment- A-antibiotics;Amp-amputation (of any type);D-debridment;I&D- incision 
and drainage 
Rft- renal function test ; Ab-abnormal; N-normal 
Mortality- yes;no Cause- Sep-Sepsis; DKA-Diabetic Ketoacidosis; CRF- Chronic 
Renal Failure 
  
